Polylactide fibrous membrane coated with glucan-g-poly(L-lysine)-VAPG/nucleic acid compound and preparation method

A technology of polylactide and -VAPG, which is applied in the field of tissue engineering and gene therapy, can solve problems such as prolongation, achieve the effects of slowing down the burst release, simple and easy preparation process, and protecting biological activity

Inactive Publication Date: 2018-01-09
TIANJIN UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, loading the miR-145 complex into the electrospun fibrous membrane prolongs its circulation period and sustained slow release, thereby regulating the proliferation and phenotype of vascular smooth muscle cells in the long term and preventing intimal hyperplasia and restenosis during vascular reconstruction. Not reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polylactide fibrous membrane coated with glucan-g-poly(L-lysine)-VAPG/nucleic acid compound and preparation method
  • Polylactide fibrous membrane coated with glucan-g-poly(L-lysine)-VAPG/nucleic acid compound and preparation method
  • Polylactide fibrous membrane coated with glucan-g-poly(L-lysine)-VAPG/nucleic acid compound and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] (1) Weigh the weight average molecular weight to be 1×10 5 400 mg of PLGA (lactide: glycolide = 3:1) was dissolved in 4 mL of a mixed solvent of chloroform and N,N'-dimethylformamide with a volume ratio of 4:1, and 48 mg of F127 was added as an emulsified agent, stirred overnight at room temperature to obtain a homogeneous oily solution (O).

[0027](2) Weigh the weight average molecular weight to be 3.6×10 4 Dextran-g-poly( L -lysine)-VAPG polymer 10mg, dissolved in 2mL of DEPC water; 25μL of DEPC water was added to 1OD miRNA to prepare a miRNA solution with a concentration of 1.32mg / mL; according to the polymer / miRNA ratio of 2:1 For mass ratio, 60 μL of miRNA solution was mixed with 32 μL of polymer solution at room temperature for 15-45 min, and 68 μL of TE buffer was added to form a uniform aqueous phase solution (W).

[0028] (3) According to the water-to-oil ratio of 1:25, stir and mix 4 mL of the oil phase solution with the above 160 μL of the water phase sol...

Embodiment 2

[0030] (1) Weigh the weight average molecular weight to be 7.5×10 4 800 mg of PLGA (lactide: glycolide = 3:1) was dissolved in 4 mL of a mixed solvent of chloroform and N,N'dimethylformamide with a volume ratio of 6:1, and 44 mg of F127 was added as an emulsifier , stirring overnight at room temperature to obtain a homogeneous oily solution (O).

[0031] (2) Weigh the weight average molecular weight to be 2.1×10 4 Dextran-g-poly( L -Lysine)-VAPG polymer 10 mg, dissolved in 2 mL of DEPC water; add 25 μL of DEPC water to 1OD miRNA to prepare a miRNA solution with a concentration of 1.32 mg / mL, and follow the polymer / miRNA ratio of 3:1 60 μL of miRNA solution was mixed with 48 μL of polymer solution at room temperature for 15-45 min at room temperature, and 52 μL of TE buffer was added to form a uniform aqueous phase solution (W).

[0032] (3) According to the water-to-oil ratio of 1:25, stir and mix 4 mL of the oil phase solution with the above 160 μL of the water phase solut...

Embodiment 3

[0034] (1) Weigh the weight average molecular weight to be 5×10 4 1200mg of PLGA (lactide: glycolide = 3:1) was dissolved in 4mL of a mixed solvent of chloroform and N,N'dimethylformamide with a volume ratio of 8:1, and 40mg of F127 was added as an emulsifier , stirring overnight at room temperature to obtain a homogeneous oily solution (O).

[0035] (2) Weigh the weight average molecular weight to be 1.5×10 4 Dextran-g-poly( L -Lysine)-VAPG polymer 10 mg, dissolved in 2 mL of DEPC water; add 25 μL of DEPC water to 1OD miRNA to prepare a miRNA solution with a concentration of 1.32 mg / mL, and follow the polymer / miRNA ratio of 4:1 45 μL of miRNA solution was mixed with 48 μL of polymer solution at room temperature for 15-45 min, and 107 μL of TE buffer was added to form a uniform aqueous solution (W).

[0036] (3) According to the water-to-oil ratio of 1:20, stir and mix 4 mL of the oil phase solution with the above 200 μL of the water phase solution for 0.5-2 hours to form a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a polylactide fibrous membrane coated with a glucan-g-poly(L-lysine)-VAPG/nucleic acid compound and a preparation method. The fibrous membrane is prepared from fibers with thediameter of 600-1,200 nm and glucan-g-poly(L-lysine)-VAPG/nucleic acid compound nanoparticles with the diameter of 50-100 nm and is 60-150 mu m thick. A nucleic acid compound solution coated with a glucan-g-poly(L-lysine)-VAPG polymer serves as a water phase, a PELCL or PLGA solution is taken as an oil phase, an electrospun fibrous membrane coated with a nucleic acid compound is prepared in an emulsion electrospinning manner, complete coating of nucleic acid is realized, the bioactivity of nucleic acid is protected, burst release of nucleic acid is relieved, the burst release rate is 20% or below, nucleic acid can be sustainably released to vascular smooth muscle cells in a controlled manner, and the polylactide fibrous membrane has good biocompatibility and biodegradability and can be used for the fields of tissue engineering and gene treatment.

Description

technical field [0001] The present invention relates to a kind of glucan-g-poly( L -Lysine)-VAPG / nucleic acid complex polylactide copolymer fiber membrane and preparation method, belonging to the field of tissue engineering and gene therapy. Background technique [0002] The electrospun fiber membrane has a high specific surface area and porosity. By adjusting the electrospinning parameters, the prepared electrospun fiber membrane can better simulate the extracellular matrix environment (ECM), which is conducive to cell adhesion, growth and nutrient transfer. , has broad application prospects in the field of tissue engineering scaffolds (Rayatpisheh S, Heath DE, Shakouri A, RujitanarojPO, Chew SY, Chan-Park MB.Combining cell sheet technology and electrospunscaffolding for engineered tubular,aligned,and contractile bloodvessels.Biomaterials,2014 , 35:2713-9). Polyethylene glycol-poly(lactide-co-caprolactone) and poly(glycolide-co-lactide) are electrospun materials with good...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/22A61L27/18A61L27/20A61L27/54A61L27/58D04H1/413D04H1/435D04H1/728
Inventor 袁晓燕周培琼赵蕴慧任丽霞
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap